Journals / Klinik Psikofarmakoloji Bülteni / 2009 / Cilt: 19 - Sayı: 1

Fluvoksamin tedavisi sırasında oluşan işitme kaybı ve tinnitus: Olgu sunumu

Hearing loss and tinnitus during fluvoxamine treatment: A case report

Pages
59–63
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case was considered to be noteworthy to publish, in order to increase clinicians’ awareness of the possible side effects of SSRI’s on the auditory functions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fluvoxamine is a widely prescribed selective serotonin reuptake inhibitor (SSRI).
📊
Key Findings & Data:A 54-year-old female patient with major depression had complaints about tinnitus and hearing loss in her right ear during fluvoxamine treatment.
💡
Conclusion & Impact:This case was considered to be noteworthy to publish, in order to increase clinicians’ awareness of the possible side effects of SSRI’s on the auditory functions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fluvoxamine is a widely prescribed selective serotonin reuptake inhibitor (SSRI). Although it is known that serotonin constitutes an important network in the hearing process and there are recent studies investigating the effects of serotonin and SSRI’s on the auditory functions, its exact role is not well characterized. In this paper we present a case with hearing loss and tinnitus which developed during fluvoxamine treatment and disappeared after discontinuation of fluvoxamine. A 54-year-old female patient with major depression had complaints about tinnitus and hearing loss in her right ear during fluvoxamine treatment. There were no significant abnormalities in her medical history, she was not taking any other medications, and ear-nose-throat examination was within normal limits. Audiometry revealed mixed hearing loss and transient otoacoustic emission (TOAE) recordings revealed a low reproducibility and low signal to noise ratio in the right ear. The control investigations after discontinuation of fluvoxamine revealed that the auditory functions were restored. The hearing loss in our patient might be due to the interference of fluvoxamine with facial nerve functioning or the effects of serotonin on the auditory sensorineural transmission. This case was considered to be noteworthy to publish, in order to increase clinicians’ awareness of the possible side effects of SSRI’s on the auditory functions.

Özet

Fluvoksamin, yaygın olarak reçete edilen bir seçici serotonin geri alım inhibitörüdür (SSGİ). Serotoninin işitme süreçleri kapsamında önemli bir ağ oluşturduğu bilinmektedir. Son dönemde serotonin ve SSGİ’lerin işitme işlevleri üzerindeki etkisini inceleyen çalışmalar yapılmaktadır. Ancak, serotoninin işitme üzerindeki etkisi net olarak belirlenememiştir. Bu yazıda, şuvoksamin tedavisi sırasında tinnitus ve işitme kaybı gözlenen ve tedavi kesildikten sonra bu yakınmaların ortadan kalktığı bir olgu sunulmuştur. Majör depresyon tanısıyla şuvoksamin kullanmakta olan 54 yaşında kadın hastada, sağ kulakta tinnitus ve işitme kaybı şikayetleri ortaya çıktı. Hastanın tıbbi öyküsünde herhangi bir özelliğe rastlanmadı, başka herhangi bir ilaç kullanmıyordu ve kulak-burun-boğaz muayenesi tamamen normaldi. Odiometride, sağ kulakta mikst işitme kaybı gözlendi. Geçici otoakustik emisyon kayıtlarında, sağ kulakta düşük üretilebilirlik (reproducibility) ve düşük sinyal/gürültü oranı olduğu gözlendi. Fluvoksamin tedavisi kesildikten sonra yapılan kontrol incelemelerinde, işitme işlevleri normale dönmüştü. Hastamızda oluşan işitme kaybının, şuvoksamin’in fasiyal sinir işlevleri üzerindeki etkisine ve/ veya serotoninin işitsel sensorinöral iletim üzerindeki etkisine bağlı olabileceği düşünülmüştür. Olgu, klinisyenlerin SSGİ kullanımı sırasında oluşabilecek işitsel yan etkiler konusunda farkındalığını artırmak amacıyla sunulmaya değer bulunmuştur.

🔖

Cite This Article

DEREKÖY, F. S., YILMAZ, D., GÜNDOĞAR, D. (2022). Fluvoksamin tedavisi sırasında oluşan işitme kaybı ve tinnitus: Olgu sunumu. Klinik Psikofarmakoloji Bülteni, Cilt: 19 - Sayı: 1, 59–63. https://ajindex.com/articles/574280

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Carrasco JL, Sandner C. Clinical effects of pharmacologic variations in selective serotonin reuptake inhibitors: an overview. Int J Clin Pract 2005; 59: 1428-1434 2. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507-533 3. Cruz OLM, Kase CA, Sanchez M, Barbosa F, Barros FA. Serotonin reuptake inhibitors in auditory processing disorders in elderly patients: preliminary results. Laryngoscope 2004; 114: 1656-1659 4. Liu J, Xuepei L, Wang L, Dong Y, Han H, Liu G. Effects of salicylate on serotoninergic activities in rat inferior colliculus and auditory cortex. Hear Res 2003; 175: 45-53 5. Gopal KV, Briley KA, Goodale ES, Hendea OM. Selective serotonin reuptake inhibitors treatment effects on auditory measures in depressed female subjects. Eur J Pharmacol 2005; 520: 59-69 6. Tadros SF, D’Souza M, Zettel ML, Zhu XX, Lynch-Erhardt M, Frisina RD. Serotonin 2B receptor: Upregulated with age and hearing loss in mouse auditory system. Neurobiol Aging 2006 (in press) 7. Xia Y, Gopal KV, Gross GW. Differential acute effects of fluoxetine on frontal and auditory cortex in vitro. Brain Res 2003; 973: 151-160 8. Robinson SK, Viirre ES, Stein MB. Antidepressant therapy in tinnitus. Hear Res 2006 (in press) 9. Feighner JP. A comparative trial of fluoxetine and amitriptyline in patients with a major depressive disorder. J Clin Psychiatry 1985; 46: 369-372 10. Glaxo-Smith-Kline. Product information Paxil. Philadelphia: Glaxo Smith Kline, 2002 11. Simpson JJ, Davies WE. A review of evidence in support of a role for 5-HT in the perception of tinnitus. Hear Res 2000; 145: 1-7 12. Baguley DM. Mechanisms of tinnitus. Br Med Bull 2002; 63: 195-212 13. Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impairment during fluoxetine therapy (Letter to the Editor). Am J Psychiatry 1990; 147: 947-948 14. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J et al. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5: 322-329 15. Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307: 117-119 16. Urani A, Romieu P, Portales Casamar E, Roman FJ, Maurice T. The antidepressant-like effect induced by the sigma(1) receptor agonist igmesine involves modulation of intracellular calcium mobilization. Psychopharmacology 2002; 163: 26-35 17.